Aadil Najeed, Senior Resident of Government Medical College Srinagar, shared a post on LinkedIn:
“Radiation Therapy: From Palliative Tool to Standard of Care in Stage IV NSCLC
Radiation therapy has long been a cornerstone of cure in Stage I–III NSCLC.
Now, emerging evidence and IASLC consensus signal a paradigm shift: Definitive RT to the primary tumor is becoming a standard component in selected Stage IV patients
What’s changing?
- RT is no longer just palliative in metastatic disease
- Primary tumor control translates into survival benefit
- Maximum impact seen in EGFR+ (AGA) oligometastatic disease
Key clinical takeaways
- RT + TKI → improved PFS and OS
- Early consolidative RT is preferred (don’t wait for progression)
- Higher-dose RT improves local control
- Careful integration with immunotherapy (toxicity risk)
Why this matters
- Curative in Stage I–III
- Now disease-modifying in Stage IV (selected patients)
Radiation therapy is evolving from a local modality to a survival-modifying tool
Bottom line: Radiation Oncology is no longer just about local control — it is shaping systemic outcomes.”
Other articles featuring Aadil Najeed on OncoDaily.
